The Generic Biosimilar Medicines Association and the Biologics Prescriber Collaborative have released new information on biosimilars, aimed at physicians and the public, respectively.
New information on biosimilars from Australia and the US
Biosimilars/General
|
Posted 04/05/2020
0
Post your comment

The Generic Biosimilar Medicines Association (GBMA) represents generic and biosimilar medicine manufacturers in Australia. In 2019, the Association launched a new educational programme on biosimilars for healthcare professionals, as well as a ‘Biosimilar Hub’ aimed at patients, prescribers and pharmacists [1].
More recently, the GBMA has released an online course on biosimilars specifically for General Practitioners (GPs). The course is accredited by the Royal Australian College of General Practitioners (RACGP) and has three key elements, summarized below:
Expertise
- How biosimilars contribute to the sustainability of the healthcare system
- The clinical development and regulatory processes involved in approving a biosimilar
Patient care
- Explaining biosimilars to patients
- Managing patient concerns about biosimilars
Practice
- Criteria that must be met to substitute a reference biological for a biosimilar
Similarly, the Biologics Prescriber Collaborative (BPC), a project of AfPA (Alliance for Patient Access), which works to ensure that policies are in place to promote the safe use of biologicals and biosimilars in the US, has released a new infographic on the US biosimilars pathway.
The biosimilars pathway is also known as the Biologics Price Competition and Innovation Act of 2019 (BPCI Act), which was passed in 2009 and created an abbreviated pathway for the approval of biosimilars in the US.
Information from the BPC shows that in the 10 years since Congress established the biosimilar pathway:
- 26 biosimilars have been approved
- 15 biosimilars are available on the market
- 1,000 biosimilars are in the pipeline
The infographic also explains the five main treatment groups of approved biosimilars (oncology, haematology, gastroenterology, rheumatology and dermatology) and states that 70% of physicians are confident in the standards for biosimilar interchangeability, according to the 2018 data from the BPC.
Related articles
Biosimilars highlights: 2019
Biosimilars approved in the US
Biosimilars approved in Australia
Reference
1. GaBI Online - Generics and Biosimilars Initiative. New biosimilar guide for pharmacists in Australia [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 May 4]. Available from: www.gabionline.net/Policies-Legislation/New-biosimilar-guide-for-pharmacists-in-Australia
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.
Source: BPC; GBMA
Research
Positive safety and efficacy primary endpoint results for AVT05 (golimumab proposed biosimilar)
News
EMA recommends approval for tocilizumab biosimilar Avtozma and filgrastim biosimilar Zefylti
Ustekinumab biosimilars Yesintek, Steqeyma, and Otulfi approved by FDA, EMA and Health Canada
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Biologicals and biosimilars available for IBD in Canada
Biosimilar medicines on the Pharmaceutical Benefits Scheme in Australia
SBR issues consensus on interchangeability of reference products and biosimilars
Innovative direct purchase agreement sees adalimumab biosimilar prices slashed
Biosimilar medicines on the Pharmaceutical Benefits Scheme in Australia

Biosimilars/General Posted 20/11/2024
SBR issues consensus on interchangeability of reference products and biosimilars

Biosimilars/General Posted 13/11/2024
Innovative direct purchase agreement sees adalimumab biosimilar prices slashed

Biosimilars/General Posted 15/10/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment